SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?


To: Pierre Borczuk who wrote (345)8/12/1999 3:17:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
J Clin Invest 1999 Aug;104(3):281-90

Mixed chimerism induced without lethal conditioning prevents T cell- and
anti-Galalpha1,3Gal-mediated graft rejection.

Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M

Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston,
Massachusetts 02129, USA.

[Medline record in process]

Galalpha1,3Gal-reactive (Gal-reactive) antibodies are a major impediment to pig-to-human xenotransplantation. We
investigated the potential to induce tolerance of anti-Gal-producing cells and prevent rejection of vascularized grafts in the
combination of alpha1,3-galactosyltransferase wild-type (GalT(+/+)) and deficient (GalT(-/-)) mice. Allogeneic (H-2
mismatched) GalT(+/+) bone marrow transplantation (BMT) to GalT(-/-) mice conditioned with a nonmyeloablative regimen,
consisting of depleting CD4 and CD8 mAb's and 3 Gy whole-body irradiation and 7 Gy thymic irradiation, led to lasting
multilineage H-2(bxd) GalT(+/+) + H-2(d) GalT(-/-) mixed chimerism. Induction of mixed chimerism was associated with a
rapid reduction of serum anti-Gal naturally occurring antibody levels. Anti-Gal-producing cells were undetectable by 2 weeks
after BMT, suggesting that anti-Gal-producing cells preexisting at the time of BMT are rapidly tolerized. Even after
immunization with Gal-bearing xenogeneic cells, mixed chimeras were devoid of anti-Gal-producing cells and permanently
accepted donor-type GalT(+/+) heart grafts (>150 days), whereas non-BMT control animals rejected these hearts within 1-7
days. B cells bearing receptors for Gal were completely absent from the spleens of mixed chimeras, suggesting that clonal
deletion and/or receptor editing may maintain B-cell tolerance to Gal. These findings demonstrate the principle that induction of
mixed hematopoietic chimerism with a potentially relevant nonmyeloablative regimen can simultaneously lead to tolerance
among both T cells and Gal-reactive B cells, thus preventing vascularized xenograft rejection.